Go or no go? Lecanemab’s destiny approaches
2023 begins with FDA decisions for Eisai’s Alzheimer’s project and Pfizer’s zavegepant, with an adcom for Cidara’s rezafungin.
CTAD 2022 – Lexeo takes baby steps towards Alzheimer’s gene therapy
In targeting a genetic cause of the disease, Lexeo reckons it could outdo anti-amyloid antibodies, but has a long way to go.
CTAD 2022 – gantenerumab’s shortcomings keep amyloid hypothesis alive
The failure of Roche’s Graduate 1 and 2 studies can be explained away by insufficient amyloid clearance.
CTAD 2022 – lecanemab data hold up, with a big but
Keenly awaited results reveal no smoking gun, but lecanemab’s modest activity appears not that different from Aduhelm’s.
Go or no go? Mirati heads to the FDA
TG Therapeutics and Gilead also await a verdict, and Cytokinetics is set for a panel.
Developers take another shot at an Alzheimer's vaccine
But the current leader, Vaxxinity, will have to convince its doubters if it is to hook a partner.
